ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in “double hit” lymphoma cells

Overview of attention for article published in Leukemia & Lymphoma, January 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

twitter: 4 X users

patent: 7 patents

Readers on

mendeley: 37 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 5 X posts from 4 X users, with an upper bound of 42,270 followers.

ABT-199 has a promising activity in #DHL; possible combinations? @tdhlf @adampetrich: mire studies coming. http://t.co/1N9TwIaKti

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 1 additional X posts.